Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial
Journal of Gynecologic Oncology · 2026
DOI: 10.3802/jgo.2026.37.e98 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Yingjie Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Fertility Preservation, Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hubei Provincial Science and Technology Program, China Postdoctoral Science Foundation, National Clinical Research Center of Obstetrics and Gynecology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The increasing prevalence of cervical cancer in younger women highlights the need for personalized fertility-preserving treatment strategies. Current fertility preservation approaches for early-stage cervical cancer primarily involve cervical conization and radical trachelectomy. However, removing part or all of the cervix can negatively impact reproductive outcomes. These procedures increase the risk of preterm birth and miscarriage, and sometimes require additional surgery due to positive margins. Combined chemotherapy and immune checkpoint inhibitor (ICI) therapy has demonstrated promising efficacy and tolerability in treating locally advanced cervical cancer. However, its role as a non-surgical, fertility-sparing treatment for stage IB1 disease remains unclear. METHODS: This multicenter, single-arm, phase II trial is designed to evaluate the efficacy and safety of combining chemotherapy with camrelizumab as a fertility-preserving strategy for patients with International Federation of Gynecology and Obstetrics 2018 stage IB1 cervical cancer. Key inclusion criteria include: 1) pathologically confirmed cervical squamous cell carcinoma, 2) transformation zone of TZ1 or TZ2, 3) programmed death-ligand 1 combined positive score ≥1, and 4) age 18-45 with a desire to preserve fertility. Key exclusion criteria include being unable to achieve pregnancy even with assisted reproductive technology; autoimmune disease requiring systemic therapy; and prior exposure to ICIs or contraindications to study drugs. A total of 40 patients will be recruited from multiple centers across China. Enrolled patients will receive 1 cycle of chemotherapy (nab-paclitaxel + cisplatin), 2 cycles of chemotherapy combined with camrelizumab, and 3 cycles of camrelizumab alone. Those who achieve tumors ≤2 cm, no new lesions, and a biopsy-proven pathological response will undergo cervical conization combined with pelvic lymphadenectomy or pelvic lymphadenectomy alone. The primary endpoint is the pathological complete response rate. Secondary endpoints include the negative human papillomavirus conversion rate, pregnancy rate, miscarriage rate, live birth rate, preterm birth rate, adverse events, quality of life, event-free survival, and overall survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06289062.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and…
ORCID-Profile: Yingjie Hu, Shuting Chen, Hanxu Cheng, Yingyan Han, Chaoyang Sun, Gang Chen, Jing Chen, Kezhen Li
Förderung
- Hubei Provincial Science and Technology Program
- China Postdoctoral Science Foundation
- National Clinical Research Center of Obstetrics and Gynecology
- National Natural Science Foundation of China
Zitieren
APA
Hu, Y., Chen, S., Cheng, H., Han, Y., Sun, C., Chen, G., Chen, J., & Li, K. (2026). Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e98
Vancouver
Hu Y, Chen S, Cheng H, Han Y, Sun C, Chen G, et al. Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e98
BibTeX
@article{Hu2026,
author = {Hu, Yingjie and Chen, Shuting and Cheng, Hanxu and Han, Yingyan and Sun, Chaoyang and Chen, Gang and Chen, Jing and Li, Kezhen},
title = {Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial},
journal = {Journal of Gynecologic Oncology},
year = {2026},
doi = {10.3802/jgo.2026.37.e98}
}
EUVIMED